Literature DB >> 8889351

Recruitment experience in the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study.

P K Whelton1, J Y Lee, J W Kusek, J Charleston, J DeBruge, M Douglas, M Faulkner, P G Greene, C A Jones, S Kiefer, K A Kirk, B Levell, K Norris, S N Powers, T M Retta, D E Smith, H Ward.   

Abstract

Several approaches for recruitment of African American adults with renal insufficiency due to hypertension (glomerular filtration rate between 25 and 70 ml/min/1.73 m2) were explored in the Pilot Study for the African American Study of Kidney Disease and Hypertension (AASK). Over a period of 42 weeks, prescreening information was obtained on 2880 individuals, of whom 498 (17%) were evaluated at a screening visit. Two hundred and twenty-five (8%) had an 125I-iothalamate assessment of glomerular filtration rate. Ninety-four of 97 participants who met all the study eligibility criteria were enrolled in the trial. The most common reasons for ineligibility during screening were absence of renal insufficiency or hypertension, presence of diabetes mellitus, and a body mass index above the acceptable level. Overall, an average of 31 prescreen contacts and 8 screening visits were conducted for every randomization (3.3% yield from prescreening to randomization). Screening in clinical practice was the most efficient method for recruitment (12.6% yield from prescreen contact to randomization compared to 1.1% from mass mailing campaigns, 1.3% from mass media campaigns, and 1.7% from referrals by patients with end-stage renal disease). Randomization yields increased with progressively higher age ranges (2.4%, 3.3%, and 6.0% prescreen to randomization yields for those aged < or = 50, 51-60, and 61-70, respectively). A slight majority (51%) of the prescreen contacts were women, but 75% of the randomized participants were men. Our results suggest that clinic-based screening is an effective approach for recruitment of African Americans with hypertension and renal insufficiency into clinical trials. They also suggest that enrollment of African American women in such studies is a special challenge.

Entities:  

Mesh:

Year:  1996        PMID: 8889351     DOI: 10.1016/s0197-2456(96)00087-6

Source DB:  PubMed          Journal:  Control Clin Trials        ISSN: 0197-2456


  7 in total

1.  African-American participation in clinical trials: situating trust and trustworthiness.

Authors:  L M Crawley
Journal:  J Natl Med Assoc       Date:  2001-12       Impact factor: 1.798

Review 2.  African Americans, hypertension and the renin angiotensin system.

Authors:  Sandra F Williams; Susanne B Nicholas; Nosratola D Vaziri; Keith C Norris
Journal:  World J Cardiol       Date:  2014-09-26

Review 3.  Recruiting vulnerable populations into research: a systematic review of recruitment interventions.

Authors:  Stacy J UyBico; Shani Pavel; Cary P Gross
Journal:  J Gen Intern Med       Date:  2007-03-21       Impact factor: 5.128

Review 4.  Recruiting underserved populations to dermatologic research: a systematic review.

Authors:  Chaya R Spears; Bridgit V Nolan; Jenna L O'Neill; Thomas A Arcury; Joseph G Grzywacz; Steven R Feldman
Journal:  Int J Dermatol       Date:  2011-04       Impact factor: 2.736

Review 5.  Treatment of octogenarians: should we and how.

Authors:  Robert A Phillips; John B Kostis
Journal:  J Clin Hypertens (Greenwich)       Date:  2004-05       Impact factor: 3.738

6.  Willingness to participate in clinical trials among African Americans and whites previously exposed to clinical research.

Authors:  Raegan W Durant; Anna T Legedza; Edward R Marcantonio; Marcie B Freeman; Bruce E Landon
Journal:  J Cult Divers       Date:  2011

7.  Recruitment of African Americans with chronic renal insufficiency into a multicenter clinical trial: the african american study of kidney disease and hypertension.

Authors:  Robert A Phillips; Marquetta Faulkner; Jennifer Gassman; Luzmaria Jaen; John W Kusek; Keith Norris; Akinlolu Ojo
Journal:  J Clin Hypertens (Greenwich)       Date:  2004-08       Impact factor: 3.738

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.